A Physiologically-Based Pharmacokinetic Model for Targeting Calcitriol-Conjugated Quantum Dots to Inflammatory Breast Cancer Cells.
Animals
Antineoplastic Agents
/ administration & dosage
Breast Neoplasms
/ drug therapy
Calcitriol
/ administration & dosage
Cell Line, Tumor
Drug Delivery Systems
/ methods
Female
Humans
Immunoconjugates
/ administration & dosage
Mice
Models, Biological
Mucin-1
/ immunology
Quantum Dots
/ administration & dosage
Xenograft Model Antitumor Assays
Journal
Clinical and translational science
ISSN: 1752-8062
Titre abrégé: Clin Transl Sci
Pays: United States
ID NLM: 101474067
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
26
04
2019
accepted:
17
05
2019
pubmed:
16
7
2019
medline:
1
9
2020
entrez:
16
7
2019
Statut:
ppublish
Résumé
Quantum dots (QDs) conjugated with 1,25 dihydroxyvitamin D3 (calcitriol) and Mucin-1 (MUC-1) antibodies (SM3) have been found to target inflammatory breast cancer (IBC) tumors and reduce proliferation, migration, and differentiation of these tumors in mice. A physiologically-based pharmacokinetic model has been constructed and optimized to match experimental data for multiple QDs: control QDs, QDs conjugated with calcitriol, and QDs conjugated with both calcitriol and SM3 MUC1 antibodies. The model predicts continuous QD concentration for key tissues in mice distinguished by IBC stage (healthy, early-stage, and late-stage). Experimental and clinical efforts in QD treatment of IBC can be augmented by in silico simulations that predict the short-term and long-term behavior of QD treatment regimens.
Identifiants
pubmed: 31305024
doi: 10.1111/cts.12664
pmc: PMC6853145
doi:
Substances chimiques
Antineoplastic Agents
0
Immunoconjugates
0
MUC1 protein, human
0
Mucin-1
0
Calcitriol
FXC9231JVH
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
617-624Informations de copyright
© 2019 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics.
Références
Exp Ther Med. 2016 Oct;12(4):2377-2382
pubmed: 27703501
Ann Intern Med. 1984 Jan;100(1):1-6
pubmed: 6546327
South Med J. 2003 Feb;96(2):164-7
pubmed: 12630642
Int J Cancer. 2013 May 15;132(10):2283-94
pubmed: 23129218
Br J Pharmacol. 2009 Jul;157(6):907-21
pubmed: 19508398
Toxicol Appl Pharmacol. 1990 Mar 1;102(3):497-513
pubmed: 2315918
J Drug Target. 1998;6(4):261-72
pubmed: 9894694
Dermatol Ther. 2010 Jan-Feb;23(1):2-12
pubmed: 20136904
Mol Cancer Ther. 2004 Mar;3(3):373-81
pubmed: 15026558
ACS Nano. 2010 Nov 23;4(11):6303-17
pubmed: 20945925
Clin Exp Metastasis. 2012 Dec;29(8):971-9
pubmed: 22610818
Environ Sci Technol. 2008 Aug 15;42(16):6264-70
pubmed: 18767697
Toxicol Lett. 2011 Aug 28;205(2):154-62
pubmed: 21641977
Toxicol Ind Health. 1997 Jul-Aug;13(4):407-84
pubmed: 9249929
Clin Breast Cancer. 2013 Apr;13(2):88-94
pubmed: 23218473
CA Cancer J Clin. 2010 Nov-Dec;60(6):351-75
pubmed: 20959401